Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
|
|
- Gabriella Davidson
- 5 years ago
- Views:
Transcription
1 Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
2 Significant impact of ASCT before the availability of novel agents?
3 Randomized trials: Single auto-sct vs. conventional chemotherapy Author CR (%) PFS (meses) OS (meses) Attal et al (IFM), vs 5 28 vs vs 42 Auto-SCT Gold-standard for initial treatment in patients younger than 65 yrs.? Morgan et al (MRC), vs 9 32 vs vs 42 Only chemosensitive patients Bladé et al (PETHEMA), vs vs vs 65 Higher chemotherapy intensity Fermand et al (GMA), vs 6 25 vs vs 48 Barlogie et al (US Intergroup), vs vs vs 53
4 Who benefit from ASCT?
5 TTP according response to transplant (CR vs. PR) 1,0 0,9 0,8 Cumulative Proportion Surviving 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0,0-0,1 PR Median: 1.3 yrs CR Median: 6.1 yrs Years P= Rovira et al., EBMT 2009
6 Overall survival according response to transplant (CR vs. PR) 1,0 0,9 Cumulative Proportion Surviving 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0,0 PR Median: 4 yrs CR Median: 9.6 yrs Years p= Rovira et al., EBMT 2009
7 Which are the factors associated with CR postransplant?
8 CR after HDT According to Tumor Burden Pretransplant M-protein size CR (%) P-value Serum* - < 10 g/l g/l 15 Serum and urine** - < 10 g/l and < 0.5 g/24h g/l and / or 0.5 to 1 g/24h > 20 g/l and / or > 1 g/24h 7 *Alexanian et al, BMT 2001; 27: ** Nadal et al, BMT 2004; 33: 61-64
9 Do patients who achieve CR with primary therapy benefit from HDT/ASCT intensification?
10 Patients achieving CR with standard-dose therapy Similar PFS and OS to those in CR after HDT/ASCT* Need for controlled trials *Alexanian et al, BMT 2001; Wang et al, BMT 2010
11 Is ASCT a useful salvage therapy for patients with primary refractory myeloma?
12 HDT/SCT in Primary Refractory Myeloma Author, yr No. Pts Age (yrs.) B2M (mg/l) CR (%) EFS (yrs) OS (yrs) Alexanian et al, Blood, 1994 Vesole et al, Blood 1994 Singhal et al, BMT, 2002 Kumar et al, BMT, 2004 Alexanian et al, BMT * 7* * In patients achiving CR after HDT/SCT
13 SPANISH TRIAL PETHEMA / GEM-2000 Primary Refractory patients VBMCP/VBAD Bu/MEL-140 or MEL-200 / ASCT 81 refractory 50 stable disease (62%) 31 progressive disease (38%) CVB/ASCT or Allo-RIC* *Fludarabine/Melphalan-140
14 Overall Survival: Progressive vs Chemosensitive Disease vs No-change 1,0 0,9 Cumulative Proportion Surviving 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 Non-responsive, non-progressive Progressive disease Chemosensitive 0, Years
15 Will induction with novel agents improve the postransplant outcome?
16 Autologous transplantation Up-front therapy Pre and Post-ASCT CR Rate with old Regimens* Regimen Pre-ASCT Post-ASCT Dexa/VAD 5% 35% Cyclophosphamide/Dexa 7% 32% VBMCP/VBAD 10% 35% *Bladé et al. Blood 2010;115: ; Bladé et al. Haematologica 2010;95:702-4; Harousseau et al. ASH 2009 (abstract 353); Mellqvist et al. Cancer 2008;112:129-35; Rosiñol et al, ASH 2009 (abstract 130)
17 Autologous transplantation Up-front therapy Pre and Post-ASCT CR Rate with Novel Regimens* Regimen Pre-ASCT Post-ASCT Thal/Dex 6% 23-34% Vel/Dex 12% 33% PAD-1 24% 43% VTD 21-30% 43-52% Total Therapy III** - 56% at 2 yrs **VTD-PACE + Tandem ASCT + VTD/TD *Cavo et al, ASH 2009 (abstract 351); Rosiñol et al, ASH 2009 (abstract 130); Harousseau et al, Haematologica 2006; 91: ; Rosiñol et al, JCO 2007; 25: ; Popat et al, BJH 2008; 141: 512-6; Barlogie et al, BJH 2007; 138:
18 Best Pre-transplant Induction Old drugs vs. gentle new drug approach (VEL/DEX) vs. multidrug (VTD, VRD, PAD, VTD-PACE)? Longer EFS? Longer OS? Superior long-term outcome (cure rate)?
19 ASCT in MM Refractory disease Suboptimal response to primary therapy CR with primary therapy Highly sensitive disease (not CR) No indication No indication? Need for controlled trials Likely of benefit
20 Tandem autograft?
21 Autologous transplantation Up-front therapy Single versus double (tandem) ASCT Author No. Pts RR (%) EFS mos. OS mos. Attal et al, NEJM vs 50* (p=ns) 25 vs 30 (p=0.03) 48 vs 58 (p=0.01) Cavo et al, JCO vs 47** (p=0.008) 23 vs 35 (p=0.001) 65 vs 71 (p=ns) Sonneveld et al, Haematol vs 32*** (p<0.001) 24 vs 27 (p=0.006) 50 vs 55 (p=ns) Fermand et al, IMW vs 39*** (p=ns) 31 vs 34 (p=0.75) 57 vs 73 (p=0.09) * CR/VGPR, ** CR/nCR, *** CR
22 Autologous transplantation Up-front therapy Single versus double (tandem) ASCT Author No. Pts RR (%) EFS mos. OS mos. Attal et al, NEJM vs 50* (p=ns) 25 vs 30 (p=0.03) 48 vs 58 (p=0.01) Cavo et al, JCO vs 47** (p=0.008) 23 vs 35 (p=0.001) 65 vs 71 (p=ns) Sonneveld et al, Haematol vs 32*** (p<0.001) 24 vs 27 (p=0.006) 50 vs 55 (p=ns) Fermand et al, IMW vs 39*** (p=ns) 31 vs 34 (p=0.75) 57 vs 73 (p=0.09) * CR/VGPR, ** CR/nCR, *** CR
23 Autologous transplantation Up-front therapy Single versus double (tandem) ASCT: Systematic Review and Meta-analysis on 1608 Patients* Significantly longer EFS Kumar A et al. J Natl Cancer Inst 2009; 101:
24 AnyhelptoDr. Harousseau?
25 ASCT in MM with Induction with Long-term outcome Old Drugs Total Therapy I: 16/231 patients in continued CR after a median follow-up of 12 yrs* Single ASCT: 11/95 patients in continued CR from 8 to 15 yrs** * Barlogie et al, BJH 2007 ** Rovira et al, EBMT 2009
26 GEM05MENOS65 De novo symptomatic MM <65 yrs 1st randomization VBMCP/VBAD X 4 BORTEZOMIB** X 2 THALIDOMIDE/ DEXAMETHASONE* (TD) X 6 THAL/DEX*/ BORTEZOMIB** (VTD) X 6 ASCT (MEL200) 2nd randomization INTERFERON- 2b THALIDOMIDE THALIDOMIDE/BORTEZOMIB *Thalidomide: 200 mg/day; Dexamethasone: 40 mg on days 1-4, 9-12 **Bortezomib: 1.3 mg/m 2 on days 1,4,8, and 11 TD and VTD at 4 week-interval
27 Current PHETEMA Trial: Pre- and post-asct CR rate according to the induction regimen* Pre-ASCT Post-ASCT VBMCP/VBAD+ Bortezomib 21% 38% TD 14% 24% VTD 35% 46% *Rosiñol et al, ASH 2010
28
Consolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationAdvances in therapy of multiple myeloma Joan Bladé and Laura Rosiñol
Advances in therapy of multiple myeloma Joan Bladé and Laura Rosiñol Hematology and Oncology Institute, Hematology Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain Correspondence
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationStem Cell Transplantation in Multiple Myeloma
Stem Cell Transplantation in Multiple Myeloma Michel Attal, Philippe Moreau, Herve Avet-Loiseau, and Jean-Luc Harousseau Service d Hématologie, Hôpital Purpan, Toulouse, France Multiple myeloma (MM) is
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationClinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy
Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient Upfront Transplant Versus Maintenance Therapy Noa Biran, MD, and David Vesole, MD, PhD Introduction High dose chemotherapy
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationIncorporating Novel Agents in the Transplant Setting
Optimizing Therapeutic Sequencing in Myeloma Can Induction - Autologous SCT -Consolidation-Maintenance Lead to Improved Outcome? Paul G. Richardson, MD Jerome Lipper Multiple Myeloma Center Dana-Farber
More informationTratamiento actual del mieloma multiple y papel del trasplante en la era de las nuevas drogas
Tratamiento actual del mieloma multiple y papel del trasplante en la era de las nuevas drogas IBiS INSTITUTODEBIOMEDICINADESEVILLA José A Pérez-Simón UGC Hematologia Hospital Universitario Virgen del Rocío
More information2015 Updates in Multiple Myeloma
2015 Updates in Multiple Myeloma Siddhartha Ganguly, MD, FACP Professor of Medicine Director, Lymphoma and Myeloma Blood and Marrow Transplantation Program The University of Kansas Medical Center 1 Earliest
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationTherapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
EXPERIMENTAL AND THERAPEUTIC MEDICINE 6: 977-982, 2013 Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients CHENGCHENG FU, JUAN WANG, XUE XIN, HUI LIU,
More informationAUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA. Binod Dhakal MD, MS Jeanie Esselmann, RN
AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA Binod Dhakal MD, MS Jeanie Esselmann, RN BACKGROUND OF MULTIPLE MYELOMA Accounts for 1% of all cancers, and 10% of hematological malignancies The American
More informationAutotrapianto singolo o doppio nel mieloma: è ancora lo standard?
Azienda Ospedaliera Universitaria Ospedali Riuni4 di Foggia Autotrapianto singolo o doppio nel mieloma: è ancora lo standard? Silvana F. Capalbo UOC Ematologia e Trapianto di Cellule Staminali Emopoie?che
More informationKEY WORDS: Multiple myeloma, Autologous transplantation, Induction therapy
Short Course Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma Cristina
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationKalyan Nadiminti, MBBS 4/13/18
A Single Autologous Stem Cell Transplant (ASCT) followed by two years of post-transplant therapy is safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationKEY WORDS: Multiple myeloma, Complete remission, Prognostic factor, Overall survival, Autologous stem cell transplantation
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Jin Seok Kim,
More informationDebate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 9: , 2015
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 1895-1900, 2015 Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Policy Number: 8.01.17 Last Review: 2/2018 Origination: 12/2001 Next Review: 2/2019 Policy
More informationOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
REVIEW Korean J Intern Med 2016;31:809-819 Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Ho Sup Lee 1 and Chang-Ki Min 2 1 Department of Internal Medicine,
More informationJunru Liu*, Juan Li*, Beihui Huang, Dong Zheng, Mei Chen, Zhenhai Zhou, Duorong Xu, Waiyi Zou
Original Article Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma Junru Liu*, Juan
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationAge 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant
Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant Parneet K. Cheema, Sahar Zadeh, Vishal Kukreti, Donna Reece,
More informationGIMEMA NMSG DSMM CEMSG
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance
More informationASBMT. abstract. Español de Mieloma (PETHEMA/GEM) study groups showed encouraging results in terms of response rate and progression-free
Biol Blood Marrow Transplant 19 (2013) 69e74 Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched
More informationReduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Yvonne A. Efebera, 1 Sofia R. Qureshi, 1 Suzanne M. Cole, 2 Rima Saliba, 1 Matteo Pelosini, 1 Ronak M.
More informationASBMT. Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
Biol Blood Marrow Transplant 19 (2013) 445e449 Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma Emilie Lemieux 1,y, Cyrille Hulin 2,y, Denis Caillot 3, Stéphanie Tardy
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationNew Questions About Transplantation in Multiple Myeloma
Review Article [1] September 01, 2006 By Parameswaran Hari, MD, MRCP [2], Marcelo C. Pasquini [3], and David H. Vesole, MD, PhD [4] Multiple myeloma is now the most common indication for autologous stem
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More information